Astera Labs Dropped 12% Today. Here’s Why the Scorpio Ramp Could Define the Stock in 2026
Astera Labs (ALAB) shares fell about 12% to around $318 after its Q2 earnings. The company reported adjusted EPS of $0.80 on revenue of $392.4 million, and Q3 guidance of $540 million to $560 million revenue and non-GAAP EPS of $1.16 to $1.21. Analysts cited high expectations tied to the Scorpio ramp; valuation models estimate a ~$320 target by 2028.
How this was made
The 30-second read
Why it matters
Despite an adjusted EPS and revenue beat and Q3 guidance above forecasts, the stock dropped sharply, implying investors judged the beat as insufficient relative to what the rally had already priced.
Market read
Traders are likely to focus on whether Scorpio ramp execution can justify a demanding valuation multiple after the immediate expectation reset.
What to watch
The article emphasizes valuation and ramp timing, but provides limited detail on customer concentration, gross margin trajectory, and competitive share gains that could validate or refute the premium multiple.
Background
Astera Labs’ pre-earnings rally set unusually high expectations for Scorpio-driven growth in PCIe 6 and fabric switching.
Ticker impact
Astera Labs shares fell about 12% after Q2 results and Q3 revenue guidance, as Scorpio ramp expectations were reassessed versus the pre-earnings rally.
Near-term volatility likely persists as traders reprice the pace and magnitude of the Scorpio ramp against a high exit P/E assumption.
The article cites specific Q2 EPS/revenue, Q3 guidance, and the magnitude of the same-day drop, framing it as expectation reset rather than operating deterioration.
Market effects
Highlights valuation sensitivity in AI infrastructure connectivity and switching names as investors weigh product-cycle ramps versus premium multiples.
No specific regional impact described beyond US-listed trading reaction.
AI data-center infrastructure spending remains the global demand driver referenced, but no non-US policy or supply shock is cited.
Counterpoint
The selloff may be an overreaction to expectations already priced in, while Scorpio entering volume production could still accelerate revenue beyond what the market assumed.
Key entities
- companyAstera Labs
Subject of the article, with Q2 results, Q3 guidance, and a Scorpio ramp narrative driving the post-earnings repricing.
- product_familyScorpio
Expected to become the largest product family in Q3, with Scorpio X-Series entering volume production.
- analyst_firmNeedham
Raised its price target to $425 and maintained a Buy rating after the report.
- analyst_firmTD Cowen
Lowered its price target to $375 and kept a Hold rating after the report.
